Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth

Stock Track

2024/10/30

Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.

While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.

Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1179660506"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179660506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179660506?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179660506","market":"us","top_or_hot":-1,"title":"Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth","media":"Stock Track","content":"<p>Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.</p>\n\n<p>While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.</p>\n\n<p>Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.</p>\n\n<p>While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.</p>\n\n<p>Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAGE","symbol_name":"Sage Therapeutics","start_time":0,"source_url":"","article_id":"1179660506","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179660506","pubTimestamp":1730295327,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Sage Therapeutics Inc.  plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression  market, generating $22.1 million in total revenue for the quarter , the company's overall financial performance and updates on other programs failed to impress investors.Sage reported a net loss of $93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAGE":"Sage Therapeutics"},"translate_title":"尽管Zurzuvae增长，但第三季度盈利令人失望，Sage Therapeutics股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.\nWhile Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.\nSage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}